ProCE Banner Activity

CE / CME

Indolent B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

Multimedia
Watch this on-demand webcast of a live webinar for expert discussion of how community practitioners can optimize therapy selection and manage treatment-related adverse events in patients with indolent B-cell lymphomas, such as marginal zone lymphoma and follicular lymphoma.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: August 03, 2022

Expiration: August 02, 2023

No longer available for credit.

Share

Faculty

Elizabeth Brém

Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Pallawi Torka

Pallawi Torka, MD

Assistant Professor of Oncology
Lymphoma Division
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Bristol Myers Squibb

Incyte Corporation

Target Audience

This program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with indolent B-cell lymphomas.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Order and interpret molecular profiling for appropriate patients with indolent B-cell lymphoma to guide therapy selection
  • Select treatment regimens for patients with MZL and FL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with indolent B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of indolent B-cell lymphomas

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Elizabeth Brém, MD: consultant/advisor/speaker: Acrotech Biopharma, TG Therapeutics; advisory board: ADC Therapeutics, BeiGene, Incyte, Janssen, Kite, MorphoSys, Pharmacyclics; speaker bureau: BeiGene, Incyte, Janssen, MorphoSys, Pharmacyclics, SeaGen.

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Curio, Denovo Biopharma, Epizyme/Incyte, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys AG, Pharmacyclics/Janssen, SeaGen; researcher: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Faculty Disclosure

Primary Author

Pallawi Torka, MD

Assistant Professor of Oncology
Lymphoma Division
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Pallawi Torka, MD: advisory board: ADC Therapeutics, Genentech, Kura Oncology, TG Therapeutics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant financial relationships to disclose.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant financial relationships to disclose.

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC

Jacqueline L. Olin, MS, PharmD, BCPS, FASHP, FCC, has no relevant financial relationships to disclose.

Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

Kristi Orbaugh, MSN, NP, AOCNP: speaker bureau: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, Sanofi.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-188-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 03, 2022, through August 02, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with indolent B-cell lymphomas.